Investing.com - Cognition Therapeutics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was in line with expectations. Cognition...
Cognition Therapeutics, Inc. (CGTX) reported Q2 EPS of ($0.25), $0.04 better than the analyst estimate of ($0.29).
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer’s disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer’s disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson’s disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
|Average||11.00 (+291.46% Upside)|
|No. of Analysts||4|